03 Jan 2024
AstraZeneca (AZN.L) said on Tuesday that its respiratory syncytial virus (RSV) immunization for infants developed with Sanofi (SASY.PA) has gotten approval in China.
The drug makers co-developed the RSV shot for infants and toddlers called Beyfortus, which has already been approved for use in the European Union and the United States.
Beyfortus is expected to be available in China during the upcoming 2024-2025 RSV season, the London-listed drugmaker said in a statement.
RSV, a highly contagious seasonal virus known for cold-like symptoms, is a leading cause of hospitalization in both infants and the elderly.
Regulatory applications for the drug are currently under review in Japan and several other countries, the company added.